184 related articles for article (PubMed ID: 32319571)
1. Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma.
Kobayashi Y; Yamada D; Kawai T; Sato Y; Teshima T; Yamada Y; Nakamura M; Suzuki M; Matsumoto A; Nakagawa T; Hosoi A; Nagaoka K; Karasaki T; Matsushita H; Kume H; Kakimi K
Int J Oncol; 2020 Apr; 56(4):999-1013. PubMed ID: 32319571
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
Guislain A; Gadiot J; Kaiser A; Jordanova ES; Broeks A; Sanders J; van Boven H; de Gruijl TD; Haanen JB; Bex A; Blank CU
Cancer Immunol Immunother; 2015 Oct; 64(10):1241-50. PubMed ID: 26105626
[TBL] [Abstract][Full Text] [Related]
3. Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy.
Kobayashi M; Kubo T; Komatsu K; Fujisaki A; Terauchi F; Natsui S; Nukui A; Kurokawa S; Morita T
Med Oncol; 2013 Jun; 30(2):556. PubMed ID: 23539200
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Grundbichler M; Mlineritsch B; Ressler S; Moik M; Kappacher A; Rosenlechner S; Greil R
Oncology; 2011; 80(1-2):34-41. PubMed ID: 21606662
[TBL] [Abstract][Full Text] [Related]
5. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society.
Bergmann L; Grünwald V; Maute L; Grimm MO; Weikert S; Schleicher J; Klotz T; Greiner J; Flörcken A; Hartmann A; Gauler T
Oncol Res Treat; 2020; 43(7-8):333-339. PubMed ID: 32541143
[TBL] [Abstract][Full Text] [Related]
8. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
10. Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.
Dos Santos C; Tijeras-Raballand A; Serova M; Sebbagh S; Slimane K; Faivre S; de Gramont A; Raymond E
Br J Cancer; 2015 Jan; 112(1):86-94. PubMed ID: 25422908
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma.
Gerullis H; Bergmann L; Maute L; Ecke TH; Eimer C; Bagner JW; Otto T
Med Oncol; 2010 Jun; 27(2):373-8. PubMed ID: 19399651
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.
Larkin J; Esser N; Calvo E; Tsuchihashi Z; Fiedler U; Graeser R; Kim D
Anticancer Res; 2012 Jul; 32(7):2399-406. PubMed ID: 22753696
[TBL] [Abstract][Full Text] [Related]
13. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
Chen CC; Hess GP; Liu Z; Gesme DH; Agarwala SS; Garay CC; Hill JW; Guo A
Clin Genitourin Cancer; 2012 Dec; 10(4):256-61. PubMed ID: 22682982
[TBL] [Abstract][Full Text] [Related]
14. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.
Wong MK; Yang H; Signorovitch JE; Wang X; Liu Z; Liu NS; Qi CZ; George DJ
Curr Med Res Opin; 2014 Apr; 30(4):537-45. PubMed ID: 24329572
[TBL] [Abstract][Full Text] [Related]
15. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
16. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
Ahrens M; Scheich S; Hartmann A; Bergmann L;
Oncol Res Treat; 2019; 42(3):128-135. PubMed ID: 30799404
[TBL] [Abstract][Full Text] [Related]
17. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
18. A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.
Kanesvaran R; Watt K; Turnbull JD; Armstrong AJ; Wolkowiez MC; George DJ
Clin Genitourin Cancer; 2015 Aug; 13(4):319-327. PubMed ID: 26174223
[TBL] [Abstract][Full Text] [Related]
19. Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.
Géczi L; Bodoky G; Rokszin G; Fábián I; Torday L
Pathol Oncol Res; 2020 Oct; 26(4):2201-2207. PubMed ID: 32291570
[TBL] [Abstract][Full Text] [Related]
20. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.
Patel SB; Stenehjem DD; Gill DM; Tantravahi SK; Agarwal AM; Hsu J; Vuong W; Pal SK; Agarwal N
Clin Genitourin Cancer; 2016 Apr; 14(2):153-9. PubMed ID: 26781820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
